We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Microbiologists Display Prototype of Rapid Bacteriological Test Device

By LabMedica International staff writers
Posted on 16 May 2016
A prototype rapid diagnostic device was shown in a proof-of-concept study to identify pathogenic microorganisms with accuracy comparable to that of bacterial culture but with much shorter turnaround time.

Investigators at Massachusetts General Hospital (Boston, USA) based their device on the principle of fluorescence anisotropy, the phenomenon where the light emitted by a fluorophore has unequal intensities along different axes of polarization. More...
Their "Polarization Anisotropy Diagnostics" (PAD) device uses changes of fluorescence anisotropy when detection probes recognize target bacterial nucleic acids.

The compact PAD device included a disposable cartridge for sample preparation and multi-well detection. To perform the test bacterial RNA was extracted from a sample in the disposable plastic cartridge. Following polymerase chain reaction amplification of the RNA, the material was loaded into a two-centimeter plastic cube containing optical components that detected target RNAs based on the response to a light signal of sequence-specific detection probes. These optical cubes were placed on an electronic base station that transmitted data to a smartphone or computer where the results were displayed.

The assay was fast (two hours) compared to two to three days for classical culture. When applied to clinical samples obtained from interventional procedures, the PAD determined the overall bacterial burden, differentiated bacterial species, and identified drug resistance and virulence status.

"This prototype still needs several improvements, including building a self-contained system housing all functions, further reducing the current assay time to less than one hour and expanding the panel of probes to even more pathogens and resistance factors," said senior author Dr. Hakho Lee, associate professor of radiology at Massachusetts General Hospital. "But we can see three immediate applications for a system that can provide such rapid and accurate results - quickly diagnosing a patient's infection, determining whether antibiotic-resistant bacteria are present in a group of patients, and detecting bacterial contamination of medical devices or patient environments."

The PAD device was described in the May 5, 2016, online edition of the journal Science Advances.

Related Links:
Massachusetts General Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Thyroid Test
Anti-Thyroid EIA Test
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.